Clinical trials: Viruses
SARS-CoV-2 (Covid19)
Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects
This study will assess the safety and efficacy of TSC as a treatment for participants who are infected with SARS-CoV-2 (COVID-19).
- Trial name
- NCT04573322
- Testing
- Trans Sodium Crocetinate, Normal saline
- Where
- Romania
- Volunteers
- 25 people
- Sponsor
- Diffusion Pharmaceuticals Inc
Hepatitis B, Chronic
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection
The purpose of this study is to evaluate the efficacy of a treatment regimen of JNJ-73763989 + pegylated interferon alpha-2a (PegIFN-alpha-2a) + nucleos(t)ide analog (NA).
- Trial name
- NCT04439539
- Testing
- JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil
- Where
- 47 sites in United States, Canada and 8 more
- Volunteers
- 54 people
- Sponsor
- Janssen Research & Development, LLC
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
This phase II trial studies how well alisertib with and without rituximab works in treating patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT01812005
- Testing
- alisertib, rituximab, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
HIV Infection, Gastrointestinal Symptoms
A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System
Improvement in the rate of bacterial translocation may lead to a decrease in a chronic inflammatory response thereby decreasing CD4 destruction and HIV proliferation.
- Trial name
- NCT01184456
- Testing
- GanedenBC30, GBI-30, PTA-6086
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- AIDS Healthcare Foundation
COVID-19
A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.
The purpose of this study is to collect information on the: general information of a group of people such as their age, sex clinical information of the patients such as any other illness before having COVID 19.
- Trial name
- NCT06291831
- Testing
- nirmatrelvir, ritonavir, Controls
- Where
- Bahrain
- Volunteers
- 3,011 people
- Sponsor
- Pfizer
Influenza
A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants
This 2 arm study will evaluate the efficacy and safety of oseltamivir in the seasonal prophylaxis of influenza in immunocompromised participants (as represented by transplant recipients).
- Trial name
- NCT00412737
- Testing
- Oseltamivir
- Where
- 78 sites in United States, Belgium and 12 more
- Volunteers
- 477 people
- Sponsor
- Hoffmann-La Roche
Human Immunodeficiency Virus, Mental Health
Digital Star: HIV Prevention for Youth in Mental Health Treatment
Teenagers in mental health treatment are at greater risk for HIV and other sexually transmitted infections. This greater risk comes from many factors, some of which are related to poor emotion regulation and low self-confidence.
- Trial name
- DSTAR (NCT02921841)
- Testing
- D*STAR, D*HEALTH
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Rhode Island Hospital
Hepatitis C, Chronic
A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)
This study will provide vaniprevir 600 mg or 300 mg twice daily in combination with pegylated interferon (peg-IFN) and ribavirin (RBV) to participants with chronic hepatitis C virus (HCV) infection who did not achieve viral…
- Trial name
- NCT00943761
- Testing
- Vaniprevir 600 mg b.i.d., Vaniprevir 300 mg b.i.d., Pegylated interferon
- Volunteers
- 45 people
- Sponsor
- Merck Sharp & Dohme LLC
Influenza
Study to Evaluate Impact of School-based Influenza Vaccination on School Populations
Rates of confirmed influenza illness in vaccinated and non-vaccinated children will be compared between schools with and without vaccination programs.
- Trial name
- NCT00844051
- Testing
- School-based influenza vaccination program
- Where
- 2 sites in United States
- Volunteers
- 4,455 people
- Sponsor
- Children's Hospital Los Angeles
Hepatitis, Hepatitis C
Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects
The primary objective for this study is to determine if the addition of filibuvir to a standard regimen of peginterferon/ribavirin (pegIFN/RBV) significantly increases the proportion of subjects who achieve a sustained viral…
- Trial name
- FITNESS (NCT00987337)
- Testing
- Filibuvir
- Where
- 77 sites in United States, Belgium and 7 more
- Volunteers
- 288 people
- Sponsor
- Pfizer
Herpes Simplex
Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection
This study will evaluate the acceptability and safety of famciclovir in infants with herpes simplex infection
- Trial name
- NCT00448227
- Testing
- famciclovir
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Novartis
Diabetes Mellitus, Covid19
CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2))
The purpose of this research is to determine if CGM (continuous glucose monitors) used in the hospital in patients with COVID-19 and diabetes treated with insulin will be as accurate as point of care (POC) glucose monitors.
- Trial name
- NCT04756141
- Testing
- Continuous Glucose Monitor (CGM)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Infection, Human Immunodeficiency Virus
Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine
This study aims to compare the bioequivalence of two experimental fixed dose combination (FDC) tablets versus single entity products of dolutegravir (DTG) and lamivudine (3TC) in healthy adult subjects.
- Trial name
- NCT03078556
- Testing
- Dolutegravir, Lamivudine, Dolutegravir + Lamivudine FDC Formulation 1
- Where
- United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections, Sexually Transmitted Diseases
Mesalamine to Reduce T Cell Activation in HIV Infection
The objective of this study is to determine whether 12 weeks of mesalamine therapy added to a standard HIV treatment decreases systemic immune activation and inflammation in HIV-infected patients, possibly resulting in better…
- Conditions
- HIV Infections, Sexually Transmitted Diseases, Immune System Diseases, Lentivirus Infections
- Trial name
- NCT01090102
- Testing
- Mesalamine (5-aminosalicylic acid, Apriso)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of California, San Francisco
Hepatitis C Virus Infection
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection
The primary objective of the study is to evaluate the safety and tolerability of voxilaprevir (formerly GS-9857) alone or with sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) and antiviral activity of voxilaprevir…
- Trial name
- NCT02185794
- Testing
- Voxilaprevir, SOF/VEL
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 101 people
- Sponsor
- Gilead Sciences
Influenza
B-cell Immunity to Influenza (SLVP017)- Year 5, 2013
In this exploratory study, investigators will be looking at immune response differences between age groups and between the two different vaccines given to identical twins and vaccine-naive young adults.
- Trial name
- NCT03020537
- Testing
- Fluzone
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Stanford University
HIV Infections
HIV Screening in the Emergency Department Setting
Late diagnosis of HIV infection is believed to be responsible for high rates of HIV transmission. The purpose of this study is to determine whether targeted screening versus routine screening will identify a greater number of HIV…
- Trial name
- NCT00667186
- Testing
- Targeted Screening, Routine Screening
- Where
- United States
- Volunteers
- 9,572 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Chronic
Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus
This randomized, multi-center, Phase IV, comparative study will assess the efficacy and safety of combined peg-interferon alpha-2a (Peg-IFN-Alpha-2A) and ribavirin therapy for 48 or 72 weeks of treatment and 24 weeks of follow-up…
- Trial name
- NCT02761629
- Testing
- Peg-Interferon Alpha-2A, Ribavirin
- Where
- 17 sites in Brazil
- Volunteers
- 180 people
- Sponsor
- Hoffmann-La Roche
COVID-19
CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)
There is currently no treatment available for COVID-19, the acute respiratory illness caused by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19 that contains antibodies to the virus is a…
- Trial name
- CONCOR-1 (NCT04348656)
- Testing
- Convalescent plasma
- Where
- 73 sites in United States, Brazil and 1 more
- Volunteers
- 940 people
- Sponsor
- Hamilton Health Sciences Corporation
Coronavirus Disease 2019
Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)
The study will evaluate the safety and efficacy of orally-administered M5049 in Coronavirus disease 2019 (COVID-19) pneumonia participants who are hospitalized but not on mechanical ventilation.
- Trial name
- NCT04448756
- Testing
- M5049
- Where
- 21 sites in United States, Brazil and 1 more
- Volunteers
- 149 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.